Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

(2016) Bruno Dubois et al.   Alzheimers & Dementia

High Prevalence of Stress and Low Prevalence of Alzheimer Disease CSF Biomarkers in a Clinical Sample with Subjective Cognitive Impairment

(2016) Marie Eckerström et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

(2016) Clifford R. Jack et al.   NEUROLOGY

Considering the base rates of low performance in cognitively healthy older adults improves the accuracy to identify neurocognitive impairment with the Consortium to Establish a Registry for Alzheimer’s Disease-Neuropsychological Assessment Battery (CERAD-NAB)

(2015) Panagiota Mistridis et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Amyloid Pathology, Cognitive Impairment, and Alzheimer Disease Risk

(2015) Michael Wagner et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia

(2015) Willemijn J. Jansen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment

(2015) Alba Sierra-Rio et al.   Neurodegenerative Diseases

The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean?

(2014) Flora H. Duits et al.   Alzheimers & Dementia

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease

(2014) Frank Jessen et al.   Alzheimers & Dementia

AD dementia risk in late MCI, in early MCI, and in subjective memory impairment

(2013) Frank Jessen et al.   Alzheimers & Dementia

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study

(2013) Stephanie JB Vos et al.   LANCET NEUROLOGY

Preclinical AD predicts decline in memory and executive functions in subjective complaints

(2013) A. C. van Harten et al.   NEUROLOGY

Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints

(2012) Argonde C. van Harten et al.   Alzheimers & Dementia

Comparison of Imaging Biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging

(2012) Jennifer L. Whitwell   ARCHIVES OF NEUROLOGY

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease

(2012) D. S. Knopman et al.   NEUROLOGY

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Early and Differential Diagnosis of Dementia and Mild Cognitive Impairment

(2009) Johannes Kornhuber et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study

(2009) Pieter Jelle Visser et al.   LANCET NEUROLOGY